YEM Search

搜索结果

SNAI2

靶点ID:TCMBANKGE000281

靶点别名:SLUG; SLUGH; SLUGH1; SNAIL2; WS2D

靶点描述:snail family transcriptional repressor 2

染色体:8

染色体位置:8q11.21

靶点类型:protein-coding

HERB_ID:-

HGNC_Link:11094

OMIM_Link:602150

Ensembl_Link:ENSG00000019549

靶点对应的植物

ID	拉丁名	药名	药用植物名	功能与主治	来源	药用部位	使用民族

TCMBANKHE003732	Ganoderma Lucidum seu Japonicum		灵芝(赤芝）	Hyperlipemia, coronary heart disease, angina pectoris, septicemia, carcinoma, hepatitis, vacuity taxation, palpitation, insomnia, dizziness, fatigue hypodynamia, enduring cough and asthma, chronic bronchitis, silicosis.		dried sporocarp

靶点对应的化合物

化合物ID	化合物名	别名	分子式	分子质量	Smiles

TCMBANKIN014683	Tobacco ene		C9H6Cl6O3S		C1C2C(COS(=O)O1)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl
TCMBANKIN058205	trans-resveratrol	(E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; SRT501; AX8004672; DB02709; RP17549; NCGC00017352-05; NCGC00017352-13; NCGC00017352-19; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 4CN-0696; I06-0437; 3,4',5-Trihydroxy-trans-stilbene; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; s1396; HMS1990H15; SAM001246888; CPD000058206; CU-01000001503-3; BPBio1_000479; NCGC00024003-14; (E)-5-(p-Hydroxystyryl)resorcinol; FT-0082623; Tox21_501111; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 01R360; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Tox21_303376; MLS001055357; NCGC00024003-13; GP5884; A827984; resveratrol; NCGC00017352-09; NCGC00017352-15; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; NCGC00024003-11; D0U3EP; ACN-034773; ST057251; EU-0101111; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; HY-16561; N1848; ACT09778; NCGC00017352-17; BRD-K80738081-001-09-6; KUC104385N; 3,4',5-Trihydroxy-trans-stilbene 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; LUKBXSAWLPMMSZ-OWOJBTEDSA-N; STL; MLS001424228; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzoldiol; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol; HMS1569F17; Resveratrol, Vetec(TM) reagent grade, 98%; HMS1921N04; IDI1_002152; Resvida; KB-02515; SR-01000000163-10; NCGC00017352-08; AB00052942_31; 3,5,4'-Trihydroxystilbene; trans-Stilbene-3,4',5-triol; Tox21_110257; NCGC00024003-12; trans-3,4′,5-Trihydroxystilbene; trans-3,4',5 - trihydroxystilbene; ZB000650; ZINC6787; DSSTox_RID_78898; NCGC00024003-09; 3fts; BB_NC-2570; SRT-501; ZX-AS004941; 5-[(E)-2-(4-Hydroxyphenyl)ethenyl]benzol-1,3-diol; BRD-K80738081-001-23-7; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; NSC327430; LS-2146; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; NCGC00024003-04; DSSTox_CID_11980; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol; Prestwick3_000508; trans-Resveratrol, United States Pharmacopeia (USP) Reference Standard; Resveratrol, European Pharmacopoeia (EP) Reference Standard; NCGC00015894-02; ARONIS24568; STL146386; R 5010; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; AC1L9HIC; BSPBio_003461; REGID_for_CID_445154; C14H12O3; SR-01000000163-11; 501-36-0; C03582; SRT 501; NSC 327430; NSC-327430; Spectrum5_000552; AS-12413; Trans-3,4′ NCGC00024003-06; AKOS005720936; BG01529320; BBC/741; HMS1792H15; NCGC00258925-01; TL8003323; AB00052942-29; SR-01000000163-4; SR-01000000163-16; BSPBio_000435; Opera_ID_586; NC00349; 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-; ZX-AT013797; 375823-41-9; HMS3403H15; 3,4',5-Trihydroxystilbene; HMS2232A18; KSC-10-164; AN-865; LMPK13090005; AJ-08292; OR46018; R0071; CHEMBL165; BRD-K25591257-001-01-2; Resveratrol, E-; BBL028252; NCGC00024003-05; LP01111; UNII-Q369O8926L; CCG-38874; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; MFCD00133799; 2l98; BDBM23926; SGCUT00007; GP2549; Resveratrol, trans-; CC-34242; ST2408097; MLS001076538; AK-39118; HMS1362H15; NCGC00024003-07; ABP000376; SBB055452; NCGC00017352-16; trans-3,5,4'-Trihydroxystilbene3,4',5-Stilbenetrioltrans-Resveratrol(E)-5-(p-Hydroxystyryl)resorcinol(E)-5-(4-hydroxystyryl)benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; Tox21_110257_1; BRD-K80738081-001-06-2; Resveratrol, certified reference material, TraceCERT(R); 3,4',5-Stilbenetriol; MCULE-5678456463; J10118; BSPBio_001114; HMS2052I09; Resveratrol, >=99% (HPLC); CS-1050; SCHEMBL19425; 5[(E)-2-(4-Hydroxyphenyl)-vinyl]benzene 1,3-diol; Resveratol; (E)1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; HMS3263O04; 4jaz; AB0006623; CAS-501-36-0; CCRIS 8952; MLS000069735; trans-3,4',5-trihydroxystilbene; 4qer; Tox21_201374; to_000079; SPECTRUM1502223; BC202036; API0000480; NCGC00017352-10; CHEBI:27881; NCGC00017352-24; SY014849; 3,4',5-trihydroxy-stilbene; NCGC00017352-06; PREVENTION 8 (RESVERATROL); MolPort-002-499-801; (E)-resveratrol; BCPP000091; Prestwick_619; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; SMR000058206; cid_445154; Q369O8926L; Resveratrol, analytical standard; DSSTox_GSID_31980; NCGC00017352-11; AC-727; HMS2096F17; BS0159; 5-[2-(4-hydroxyphenyl)vinyl]-1,3-benzenediol; BRD-K80738081-001-10-4; NCGC00017352-12; MLS002222231; Resveratrol, natural; Lopac0_001111; BR-39118; CJ-00111; NCGC00017352-07; DTXSID4031980; CR-003; Stilbene, 2f; NCGC00017352-18; NCGC00024003-10; SC-11924; SR-01000000163-3; MLS002207121; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; NCGC00024003-00; HMS3649A20; KS-5047; 1,3-Benzenediol, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-; NCGC00017352-14; HSDB 7571; NCGC00024003-08; 533C1DA0-4104-42B5-9D32-9265F40857E4; RM-1812; REGID_for_CID_6240; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; BIK9013; NCGC00257465-01; GTPL8741; BG00606847; NCGC00261796-01; CHEBI:45713; SR-01000000163; Resveratrol, synthetic; SR-01000000163-9; Prestwick2_000508; N88795; 3,5,4'-Trihydroxy-trans-stilbene; resveratrol; 1,3-Benzenediol, 5-((1Z)-2-(4-hydroxyphenyl)ethenyl)-; cis-3,5,4'-trihydroxystilbene; AIDS025474; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; SPBio_002356; BPBio1_000479; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Spectrum4_001896; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; EU-0101111; ST057251; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1; resveratrol ; KBioSS_000454; 1684AH; Spectrum3_001821; STL; CHEBI:36002; SPBio_001513; IDI1_002152; Prestwick1_000508; 05F9DB2A-D7E6-4063-8E5B-F7842CF74A5E; 3,5,4'-Trihydroxystilbene; 3,4',5-trihydroxy stilbene; (Z)-resveratrol; 5-[(Z)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; trans-3,4′,5-Trihydroxystilbene; 31100-06-8; 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; Cis resveratrol; SRT-501; NSC327430; 3,4′,5-Trihydroxy-trans-stilbene; Spectrum_001148; 5-[(1Z)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00024003-04; Prestwick3_000508; NCGC00015894-02; Z-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; NCGC00017352-03; SCHEMBL1931746; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; BSPBio_003461; Bio2_000877; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1-; 31100-06-8 (DELETED); Z-Resveratrol; UNII-AUA0K06FSB; 501-36-0; C03582; AKOS025395422; KBio2_004196; KBio3_002965; Prestwick0_000508; NSC 327430; 34092_RIEDEL; KBio3_000848; NCGC00017352-02; Spectrum5_000552; MolPort-003-850-143; NCGC00024003-06; KBio2_005590; SpecPlus_000391; AC1LU7HY; AUA0K06FSB; KBioGR_000454; AIDS-025474; BSPBio_000435; cis-resveratrol; KBio2_006764; KBio2_001628; KBioGR_002457; CHEMBL87333; 3,4',5-Trihydroxystilbene; Lopac-R-5010; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; KBio2_000454; Resveratrol, (Z)-; SGCUT00007; CJ-13797; NCGC00024003-07; Resveratrol (Z)-form [MI]; NCGC00017352-01; I14-7425; DivK1c_006487; MolMap_000045; 3,4',5-Stilbenetriol; Oprea1_727238; Tocris-1418; DB-072954; NCGC00017352-04; BSPBio_001114; BDBM50131698; 434C671; LUKBXSAWLPMMSZ-UPHRSURJSA-; KBio3_000847; CAS-501-36-0; SMP1_000257; 4q93; MLS000069735; cis-5-[2-(4-Hydroxyphenyl)ethenyl]benzene-1,3-diol; ZINC00006787; (Z)-3,5,4'-trihydroxystilbene; to_000079; SPECTRUM1502223; trans-Resveratrol; R5010_SIGMA; KBio2_003022; 61434-67-1; NCGC00024003-02; NCGC00015894-01; CHEBI:27881; Resveratrol; AC-24235; (E)-resveratrol; Prestwick_619; 5-[2-(4-hydroxyphenyl)vinyl]resorcinol; SMR000058206; TNP00294; Resveratrol, Z-; ZINC12353732; Lopac0_001111; cis-3,4',5-trihydroxystilbene; NCI60_002840; 5-[(E)-2-(4-hydroxyphenyl)vinyl]resorcinol; Bio2_000397; NCGC00024003-00; (Z)-3,4',5-trihydroxystilbene; 3,5-Dihydroxy-4'-methoxystilbene; 3, 5,4'-trihydroxy-trans-stilbene; cis-3,4,5-Trihydroxystilbene; NCGC00024003-08; RM-1812; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 5-[2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; SDCCGMLS-0002998.P003; KBioSS_001628; KBio1_001431; 5-[(Z)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; CHEBI:45713; Spectrum2_001497; Prestwick2_000508; 3,5,4'-Trihydroxy-trans-stilbene	C14H12O3	228.24 g/mol	C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O
TCMBANKIN058752	shikonin	HMS1990P11; 517-89-5; ST2402660; SBB066976; BSPBio_001270; AJ-32590; NEZONWMXZKDMKF-SNVBAGLBSA-N; N1643; (+)-Shikonin; HY-N0822; DTXSID30199653; NCGC00163489-01; 517S895; MLS006010149; CS-5906; 5,8-dihydroxy-2-[(1R)-1-hydroxy-4-methylpent-3-enyl]naphthalene-1,4-dione; HMS1792P11; AB0013814; RL03907; SR-05000001466-3; (R)-(+)-Shikonin; 1,4-NAPHTHOQUINONE, 5,8-DIHYDROXY-2-(1-HYDROXY-4-METHYL-3-PENTENYL)-, (+)-; BP-30212; J-502235; NSC 252844; SR-05000001466-1; s8279; HSDB 8100; CCG-208272; C17412; SCHEMBL33969; FT-0651798; CCRIS 6492; 874325-10-7; 3IK6592UBW; AC-26871; 5,8-Dihydroxy-2-[(1R)-1-hydroxy-4-methyl-pent-3-enyl]naphthalene-1,4-dione; HMS3403P11; BRN 2058010; KB-210224; AK105374; CHEBI:81068; CTK4J4851; NCGC00163489-02; NCGC00163489-04; N2643; KS-00001FJP; AC1LA0SH; 1,4-Naphthalenedione, 5,8-dihydroxy-2-(1-hydroxy-4-methyl-3-pentenyl)-, (R)-; 5,8-dihydroxy-2-[(1r)-1-hydroxy-4-methylpent-3-en-1-yl]-1,4-naphthoquinone; TR-031448; Shikonin S; AC1Q6B9B; 1,4-Naphthalenedione, 5,8-dihydroxy-2-[(1R)-1-hydroxy-4-methyl-3-pentenyl]-; ANW-73225; Tokyo Violet; MolPort-005-932-876; Shikonine; UNII-3IK6592UBW; W-2767; 876010-87-6; CJ-31254; (+)-5,8-Dihydroxy-2-(1-hydroxy-4-methyl-3-pentenyl)-1,4-naphthoquinone; 5,8-dihydroxy-2-[(1R)-1-hydroxy-4-methylpent-3-en-1-yl]-1,4-dihydronaphthalene-1,4-dione; SR-05000001466; 1,4-Naphthalenedione,5,8-dihydroxy-2-[(1R)-1-hydroxy-4-methyl-3-penten-1-yl]-; (R)-5,8-Dihydroxy-2-(1-hydroxy-4-methylpent-3-en-1-yl)naphthalene-1,4-dione; MFCD00075680; SMR002530673; AKOS015900416; AS-13554; ZINC2015152; (-)-Shikonin; BG01580835; I664; Isoarnebin 4; HMS2089L09; 5,8-dihydroxy-2-[(1R)-1-hydroxy-4-methylpent-3-enyl]naphthalene-1,4-dione; 5,8-Dihydroxy-2-((R)-1-hydroxy-4-methyl-pent-3-enyl)-[1,4]naphthoquinone; 5,8-dihydroxy-2-[(1R)-1-hydroxy-4-methyl-pent-3-enyl]naphthalene-1,4-dione; BSPBio_001270; AIDS094462; AIDS-094462; 5,8-dihydroxy-2-[(1R)-1-hydroxy-4-methyl-pent-3-enyl]-1,4-naphthoquinone; 1,4-Naphthalenedione, 5,8-dihydroxy-2-[(1R)-1-hydroxy-4-methyl-3-pentenyl]-; NCGC00163489-01; Isoarnebin 4	C16H16O5	288.3	CC(=CCC(C1=CC(=O)C2=C(C=CC(=C2C1=O)O)O)O)C
TCMBANKIN061341	nuciferine	AC1MP6HA; Nuciferine; (R)-1,2-Dimethoxyaporphine; 4H-Dibenzo(de,g)quinoline, 5,6,6a,7-tetrahydro-1,2-dimethoxy-6-methyl-, (R)-; AIDS189198; 4H-Dibenzo(de,g)quinoline, 5,6,6a,7-tetrahydro-1,2-dimethoxy-6-methyl-, (R)- (9CI); l-5,6-Dimethoxyaporphine; AIDS-189198; 6a-beta-APORPHINE, 1,2-DIMETHOXY-; l-Nuciferine; Sanjoinine E; 475-83-2; (-)-Nucipherine; Nuciferin	C19H21NO2	295.4 g/mol	CN1CCC2=CC(=C(C3=C2C1CC4=CC=CC=C43)OC)OC

靶点对应的疾病

疾病ID	疾病名	MeSH名	HPO名	UMLS名	疾病类型

TCMBANKDI000009	Neoplasms	Abnormality of the nervous system; Neoplasm	Neoplastic Process	disease
TCMBANKDI000061	Digestive System Diseases; Neoplasms	Abnormality of the digestive system; Neoplasm	Neoplastic Process	group
TCMBANKDI000076	Neoplasms	-	Neoplastic Process	group
TCMBANKDI000078	Neoplasms; Skin and Connective Tissue Diseases	Abnormality of the integument; Neoplasm	Neoplastic Process	group
TCMBANKDI000088	Neoplasms; Respiratory Tract Diseases	Neoplasm; Abnormality of the respiratory system	Neoplastic Process	group
TCMBANKDI000092	Respiratory Tract Diseases	Abnormality of the respiratory system	Disease or Syndrome	disease
TCMBANKDI000166	-	-	Neoplastic Process	disease
TCMBANKDI000167	Neoplasms	-	Neoplastic Process	phenotype
TCMBANKDI001841	Neoplasms	-	Neoplastic Process	disease
TCMBANKDI001958	Pathological Conditions, Signs and Symptoms	Abnormality of the digestive system	Disease or Syndrome	disease
TCMBANKDI002974	Neoplasms	-	Neoplastic Process	disease
TCMBANKDI003353	Pathological Conditions, Signs and Symptoms; Neoplasms	-	Neoplastic Process	phenotype
TCMBANKDI004474	Nutritional and Metabolic Diseases	Abnormality of the musculature	Pathologic Function	phenotype
TCMBANKDI005527	Nutritional and Metabolic Diseases	-	Pathologic Function	phenotype
TCMBANKDI005528	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Nervous System Diseases	-	Congenital Abnormality	disease
TCMBANKDI006055	Pathological Conditions, Signs and Symptoms; Neoplasms	-	Neoplastic Process	disease
TCMBANKDI006121	Digestive System Diseases; Neoplasms	Abnormality of the digestive system; Neoplasm	Neoplastic Process	group
TCMBANKDI006612	Neoplasms; Female Urogenital Diseases and Pregnancy Complications	Abnormality of the genitourinary system; Neoplasm	Neoplastic Process	disease
TCMBANKDI006900	-	Abnormality of head or neck	Finding	phenotype
TCMBANKDI007091	Neoplasms	-	Neoplastic Process	phenotype
TCMBANKDI008070	Congenital, Hereditary, and Neonatal Diseases and Abnormalities	-	Disease or Syndrome	disease
TCMBANKDI008206	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases	Abnormality of the genitourinary system	Congenital Abnormality	group
TCMBANKDI009135	Neoplasms	Neoplasm; Abnormality of the skeletal system	Neoplastic Process	disease
TCMBANKDI009152	-	-	Congenital Abnormality	disease
TCMBANKDI010295	Neoplasms; Endocrine System Diseases	Abnormality of the endocrine system; Neoplasm	Neoplastic Process	disease
TCMBANKDI010793	-	Abnormality of the integument; Abnormality of head or neck	Finding	phenotype
TCMBANKDI011173	Neoplasms	-	Neoplastic Process	disease
TCMBANKDI011743	Neoplasms; Skin and Connective Tissue Diseases	Neoplasm; Abnormality of the breast	Neoplastic Process	group
TCMBANKDI012319	-	Abnormality of head or neck	Finding	phenotype
TCMBANKDI012424	Pathological Conditions, Signs and Symptoms; Neoplasms	-	Pathologic Function	phenotype
TCMBANKDI012990	Neoplasms; Skin and Connective Tissue Diseases	-	Neoplastic Process	disease
TCMBANKDI013730	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Cardiovascular Diseases	Abnormality of the cardiovascular system	Congenital Abnormality	disease
TCMBANKDI014531	Pathological Conditions, Signs and Symptoms; Neoplasms; Musculoskeletal Diseases	-	Neoplastic Process	disease
TCMBANKDI015452	Neoplasms; Endocrine System Diseases	Abnormality of the endocrine system; Neoplasm	Neoplastic Process	disease
TCMBANKDI016050	Neoplasms; Skin and Connective Tissue Diseases	-	Neoplastic Process	disease
TCMBANKDI016459	-	-	Neoplastic Process	disease
TCMBANKDI016890	Digestive System Diseases; Neoplasms	-	Neoplastic Process	disease
TCMBANKDI017024	Neoplasms; Respiratory Tract Diseases	-	Neoplastic Process	disease
TCMBANKDI017483	Neoplasms	-	Neoplastic Process	phenotype
TCMBANKDI017642	Neoplasms	Abnormality of the integument; Neoplasm	Neoplastic Process	disease
TCMBANKDI018929	Eye Diseases	Abnormality of the eye	Disease or Syndrome	disease
TCMBANKDI019337	-	Abnormality of the integument; Abnormality of head or neck	Finding	phenotype
TCMBANKDI019825	Neoplasms	-	Neoplastic Process	disease
TCMBANKDI020257	Cardiovascular Diseases	-	Disease or Syndrome	disease
TCMBANKDI021600	Neoplasms	-	Neoplastic Process	disease
TCMBANKDI022433	Respiratory Tract Diseases; Cardiovascular Diseases	-	Disease or Syndrome	disease
TCMBANKDI022473	Neoplasms	-	Neoplastic Process	disease
TCMBANKDI023140	Neoplasms; Endocrine System Diseases	Abnormality of the endocrine system; Neoplasm	Neoplastic Process	disease
TCMBANKDI023751	Pathological Conditions, Signs and Symptoms; Nervous System Diseases	Abnormality of the musculature	Finding	phenotype
TCMBANKDI024035	Neoplasms	Neoplasm	Neoplastic Process	disease
TCMBANKDI024262	-	-	Neoplastic Process	phenotype
TCMBANKDI024535	Neoplasms; Respiratory Tract Diseases	Neoplasm; Abnormality of the respiratory system	Neoplastic Process	disease
TCMBANKDI025420	Digestive System Diseases; Neoplasms	Abnormality of the digestive system; Neoplasm	Neoplastic Process	disease
TCMBANKDI027026	Neoplasms; Skin and Connective Tissue Diseases	-	Neoplastic Process	disease
TCMBANKDI030137	Skin and Connective Tissue Diseases	Abnormality of the integument	Finding	phenotype
TCMBANKDI030540	Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases	Abnormality of the genitourinary system; Neoplasm	Neoplastic Process	disease
TCMBANKDI031189	Neoplasms	Neoplasm; Abnormality of the respiratory system	Neoplastic Process	disease
TCMBANKDI031570	-	Abnormality of the nervous system	Mental or Behavioral Dysfunction	disease
TCMBANKDI032109	Pathological Conditions, Signs and Symptoms	-	Disease or Syndrome	disease